Inhibition of endothelial adhesion and invasion by breast carcinoma cells may contribute towards the anti-metastatic effects of tamoxifen

European Journal of Surgical Oncology

Volumn 22, Issue 1, 1996, Pages 27-33

  Bliss, R D ^a   Kirby, J A ^a   Browell, D A ^a   Lennard, T W J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Anti oestrogens; Basement membrane; Endothelium; Metastasis

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; FULVESTRANT; MATRIGEL; TAMOXIFEN;

ANIMAL CELL; ARTICLE; CELL ADHESION; COLORIMETRY; CONTROLLED STUDY; EMBRYO; ENDOTHELIUM; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL LINE;

EID: 0029916173     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)91319-0     Document Type: Article

References (31)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992; 339: 1-15.
2. Muss HB. The role of chemotherapy and adjuvant radiotherapy in the management of breast cancer in older women. Cancer 1994; 74: 2185-271.
3. Blomqvist CP, Elomaa I, Rissanen P. Adjuvant hormone therapy in breast cancer. Ann Med 1992; 24: 91-6.
4. Schacter LP, Rozencweig M, Canetta R, Kelly S. Overview of hormonal therapy in advanced breast cancer. Semin Oncol 1990; 17: 38-46.
5. Early Breast Cancer Trialists Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomised trials among 28,896 women. N Engl J Med 1988; 319: 1681-92.
6. Shaife SM, Liotta LA. Formation of metastasis by human breast carcinoma cells. Cancer Lett 1980; 11: 81-7.
7. Thompson EW, Katz D, Shima TB, Wakeling AE, Lippman ME, Dickson RB. ICI 164,384, a pure antagonist of estrogen-stimulated MCF-7 cell proliferation and invasiveness. Cancer Res 1989; 49: 6929-34.
8. MacNeil S, Wagner M, Kirkham PR, Blankson EA, Lennard MS, Goodall T, Rennie IG. Inhibition of melanoma cell/matrix interaction by tamoxifen. Melanoma Res 1993; 3: 67-74.
9. Miller FR, Heppner GH. Cellular interactions in metastasis. Cancer & Metastasis Rev 1990; 9: 21-34.
10. Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182,780) in tamoxifen-resistant breast cancer. Lancet 1995; 345: 29-30.
11. Wakeling AE, Dukes M, Bowler J. A potent specific pure antioestrogen with clinical potential. Cancer Res 1991; 51: 3867-73.
12. Edgell CS, McDonald CC, Graham JB. Permanent cell line expressing human Facror VIII-related antigen established by hybridization. Proc Natl Acad Sci USA 1983; 80: 3734-7.
13. Bliss RD, Kirby JA, Browell DA, Lennard TWJ. The role of beta 1 integrins in adhesion of two breast carcinoma cell lines to a model endothelium. Clin Exp Metastasis 1995; 13: 173-83.
14. Berthois Y, Katzenellenbogen JA, Katzenellenbogen BS. Phenol red in tissue culture media is a weak estrogen: implications concerning the study of estrogen-responsive cells in culture. Proc Natl Acad Sci USA 1986; 83: 2496-500.
15. Imamura H, Takao S, Aikou T. A modified invasion 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazoli um bromide assay for quantitating tumour cell invasion. Cancer Res 1994; 54: 3620-4.
16. Roehm NW, Rodgers GH, Hatfield SM, Glasebrook AL. An improved colorimetric assay for cell proliferation and viability utilising the tetrazolium salt XTT. J Immunol Methods 1991; 142: 257-65.
17. Jost LM, Kirkwood JM, Whiteside TL. Improved short- and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumour cells. J Immunol Methods 1992; 147: 153-65.
18. Dawson M. Initiation and maintenance of cultures In: Butler M, Dawson M (ed) Cell Culture LabFax. Oxford: BIOS Scientific Publishers Ltd, 1992: p. 25-42.
19. Jordan VC, Morrow M. Should clinicians be concerned about the carcinogenic potential of tamoxifen? Eur J Cancer 1994; 30A: 1714-21.
20. Lipton A, Harvey HA, Hamilton HW. Venous thrombosis as a side effect of tamoxifen treatment. Cancer Treatment Rep 1984; 68: 887-9.
21. Johnston SRD, MacLennan KA, Sacks NPM, Salter J, Smith IE, Dowsett M. Modulation of Bcl-2 and Ki-67 in Oestrogen receptor positive human breast cancer by tamoxifen. Eur J Cancer 1994; 30A: 1663-9.
22. Pollak MN, Huynh HT, Pratt Lefebvre S. Tamoxifen reduces serum insulin-like growth factor-I (IGF-I). Breast Cancer Res Treatment 1992; 22: 91-100.
23. Gagliardi A, Collins DC. Inhibition of angiogenesis by anti-oestrogens. Cancer Res 1993; 53: 533-5.
24. Furman Haran E, Maretzek AF, Goldberg I, Horowitz A, Degani H. Tamoxifen enhances cell death in implanted MCF7 breast cancer by inhibiting endothelium growth. Cancer Res 1994; 54: 5511-4.
25. Brake ME, Charlier C, Bruyneel EA, Labit C, Mareel MM, Castronovo C. Tamoxifen restores the E-Cadherin function in human breast cancer MCF7/6 cells and suppresses their invasive phenotype. Cancer Res 1994; 54: 4607-9.
26. Coopman P, Garcia M, Brunner N, Derocq D, Clarke R, Rochefort H. Anti-proliferative and anti-estrogenic effects of ICI 164,384 and ICI 182,780 in 4-OH-tamoxifen-resistant human breast cancer cells. Int J Cancer 1994; 56: 295-300.
27. DeFriend DJ, Anderson E, Bell J, Wilks DP, West CML, Mansel RE, Howell A. Effects of 4-Hydroxytamoxifen and a novel pure anti-oestrogen (ICI 182,780) on the clonogenic growth of human breast cancer cells in vitro. Br J Cancer 1994; 20:204-11.
28. Osborne CK, Hobbs K, Trent JL. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer Res Treatment 1987; 9: 111-21.
29. Vic P, Vignon F, Deroco D, Rochefort H. Effect of estradiol on the ultrastructure of the MCF-7 human breast cancer cells in culture. Cancer Res 1982; 42: 667-73.
30. Salsbury AJ. The significance of the circulating cancer cell. Cancer Treatment Rep 1975; 2: 55-72.
31. Leather AJM, Gallegos NC, Kocjan G, Savage F, Smales CS, Hu W, Boulos PB, Northover JMA, Phillips RKS. Detection and enumeration of circulating tumour cells in colorectal cancer. Br J Surg 1993; 80: 777-80.